Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 14, 2018 - Issue 12
Submit an article Journal homepage
1,173
Views
7
CrossRef citations to date
0
Altmetric
Research Paper

A phase 2 study of a combined diphtheria-tetanus-acellular pertussis vaccine with a Sabin-derived inactivated poliovirus vaccine in children

Takashi NakanoDepartment of Pediatrics, Kawasaki Medical School, Kurashiki, JapanView further author information
,
Shuji SuminoTakeda Pharmaceutical Company Limited, Osaka, JapanView further author information
,
Yohei TakanamiTakeda Pharmaceutical Company Limited, Osaka, JapanView further author information
,
Nodoka MitsuyaTakeda Pharmaceutical Company Limited, Osaka, JapanCorrespondence[email protected]
View further author information
&
Keisuke NakatomeTakeda Pharmaceutical Company Limited, Osaka, JapanORCID Iconhttp://orcid.org/0000-0002-8438-873XView further author information
ORCID Icon
Pages 2940-2949 | Received 18 Apr 2018, Accepted 22 Jul 2018, Published online: 17 Aug 2018

References

  • WHO. Wild polio and vaccine derived polio in Nigeria: disease outbreak news 6 October 2016. http://www.who.int/csr/don/06-october-2016-polio-nigeria/en/.
  • Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio vaccination: past, present and future. Future Microbiol. 2015;10:791–808. doi:10.2217/fmb.15.19.
  • Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-Derived Polioviruses. J Infect Dis. 2014;210(suppl 1):S283–S293. doi:10.1093/infdis/jiu295.
  • Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine. 2015;33:1235–1242. doi:10.1016/j.vaccine.2015.01.018.
  • WHO. Polio vaccines: WHO position paper, January 2014 – recommendations. Vaccine. 2014;32:4117–4118. doi:10.1016/j.vaccine.2014.04.023.
  • WHO Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use. 2015. http://polioeradication.org/wp-content/uploads/2016/12/GAPIII_2014.pdf.
  • Deshpande JM, Nadkarni SS, Siddiqui ZA. Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003. Indian J Med Res. 2003;118:217–223.
  • Duizer E, Rutjes S, Husman A, Schijven J. Risk assessment, risk management and risk-based monitoring following a reported accidental release of poliovirus in Belgium, September to November 2014. Euro Surveill. 2016;21(11):pii=30169. doi:10.2807/1560-7917.ES.2016.21.11.30169.
  • Bakker WA, Thomassen YE, Van’t Oever AG, Westdijk J, Van Oijen MGCT, Sundermann LC, Van’t Veld P, Sleeman E, Van Nimwegen FW, Hamidi A, et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine. 2011;29:7188–7196. doi:10.1016/j.vaccine.2011.05.079.
  • Scheifele DW, Halperin SA, Ochnio JJ, Ferguson AC, Skowronski DM. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Ped Infect Dis J. 2005;24:1059–1066. doi:10.1097/01.inf.0000190028.96152.46.
  • Schmitt HJ, Beutel K, Schuind A, Knuf M, Wagner S, Müschenborn S, Bogaerts H, Bock HL, Clemens R. Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J Pediatr. 1997;130:616–623. doi:10.1016/S0022-3476(97)70247-6.
  • Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Englund JA, Meade BD, Anderson EL, Steinhoff MC, Edwards KM. Extensive swelling after booster doses of acellular pertussis–tetanus–diphtheria vaccines. Pediatrics. 2000;105:e12. doi:10.1542/peds.105.1.e12.
  • Southern J, Waight PA, Andrews N, Miller E. Extensive swelling of the limb and systemic symptoms after a fourth dose of acellular pertussis containing vaccines in England in children aged 3-6years. Vaccine. 2017;35:619–625. doi:10.1016/j.vaccine.2016.12.017.
  • Okada K, Miyazaki C, Kino Y, Ozaki T, Hirose M, Ueda K. Phase II and III clinical studies of diphtheria-tetanus-acellular pertussis vaccine containing inactivated polio vaccine derived from Sabin strains (DTaP-sIPV). J Infect Dis. 2013;208:275–283. doi:10.1093/infdis/jit155.
  • Liao G, Li R, Li C, Sacks-Davis R, Page K, Thomas DL, Osburn WO, Cox AL, Aitken CK, Hickman M, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, positive-controlled trial. J Infect Dis. 2012;205:237–243. doi:10.1093/infdis/jis213.
  • Verdijk P, Rots NY, Van Oijen MGCT, Weldon WC, Oberste MS, Okayasu H, Sutter RW, Bakker WAM. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminium hydroxide in infants. Vaccine. 2014;39:4938–4944. doi:10.1016/j.vaccine.2014.07.029.
  • WHO. Pertussis vaccines: WHO position paper – august 2015. Wkly Epidemiol Rec. 2015;35:433–458.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.